Certara Overview

  • Year Founded
  • 1979

Year Founded

  • Status
  • Public

  • Employees
  • 1,391

Employees

  • Stock Symbol
  • CERT

Stock Symbol

  • Investments
  • 22

  • Share Price
  • $16.08
  • (As of Friday Closing)

Certara General Information

Description

Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.

Contact Information

Website
www.certara.com
Formerly Known As
Tripos
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 100 Overlook Center
  • Suite 101
  • Princeton, NJ 08540
  • United States
+1 (415) 000-0000

Certara Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Certara Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.08 $16.01 $11.81 - $19.87 $2.59B 160M 598K -$0.39

Certara Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 2,925,830 2,842,719 2,660,815 4,416,264
Revenue 360,690 354,337 335,644 286,104
EBITDA 19,121 23,844 88,998 58,577
Net Income (61,398) (55,357) 14,731 (13,266)
Total Assets 1,542,378 1,563,140 1,572,922 1,511,730
Total Debt 302,423 302,567 308,134 308,380
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Certara Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Certara‘s full profile, request access.

Request a free trial

Certara Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug
Drug Discovery
Princeton, NJ
1,391 As of 2023
00000
000000000 00 00000

000000

irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nul
0000000000000
Vancouver, Canada
000 As of 0000
00000
00000000 00000

00000

, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
0000000000000
Seattle, WA
00 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Certara Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AbCellera Formerly VC-backed Vancouver, Canada 000 00000 00000000 00000
Cyrus Biotechnology Venture Capital-Backed Seattle, WA 00 000.00 00000000000 000.00
BioBlocks Corporate Backed or Acquired Hamilton, NJ 0 000000&0
SeraCare Formerly PE-Backed Milford, MA 000 000000&0
Recursion Pharmaceuticals Formerly VC-backed Salt Lake City, UT 000 00.000 00000000 00.000
You’re viewing 5 of 13 competitors. Get the full list »

Certara Patents

Certara Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240200144-A1 Methods and apparatus utilising liquid biopsy to identify and monitor pharmacodynamic markers of disease Pending 10-Aug-2021 0000000000
EP-4384641-A1 Methods and apparatus utilising liquid biopsy to identify and monitor pharmacodynamic markers of disease Pending 10-Aug-2021 0000000000
US-20220265654-A1 Dosage regimens for parp7 inhibitors Inactive 16-Feb-2021 0000000000 0
US-20210103694-A1 Methods for automated filling of columns in spreadsheets Active 07-Oct-2019 00000000000
US-11132492-B2 Methods for automated filling of columns in spreadsheets Active 07-Oct-2019 G06F16/3329 00
To view Certara’s complete patent history, request access »

Certara Executive Team (31)

Name Title Board Seat
William Feehery Chief Executive Officer & Board Member
Leif Pedersen President & Chief Commercial Officer
Drayton Virkler President
Patrick Smith President
John Gallagher Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
You’re viewing 5 of 31 executive team members. Get the full list »

Certara Board Members (20)

Name Representing Role Since
0000000 0000000 Self Board Member 000 0000
0000 000000 Certara Board Member 000 0000
00000 0000000 000 Certara Chairman & Board Member 000 0000
00000 00000000 Certara Board Member 000 0000
00000000 00000 Self Board Member 000 0000
You’re viewing 5 of 20 board members. Get the full list »

Certara Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Certara Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Certara‘s full profile, request access.

Request a free trial

Certara Investments & Acquisitions (22)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ChemAxon 09-Jul-2024 0000000000 0000 Enterprise Systems (Healthcare) 0000000 0
Applied BioMath 12-Dec-2023 0000000000 000.00 Drug Discovery 0000000 0
Formedix 10-Oct-2023 0000000000 000.00 Other Healthcare Technology Systems 000 00000
Drug Interaction Solutions 20-Jun-2023 0000000000 00.000 Decision/Risk Analysis 0000000 0
Vyasa Analytics 28-Dec-2022 Merger/Acquisition 000.00 Media and Information Services (B2B) 0000000 0
You’re viewing 5 of 22 investments and acquisitions. Get the full list »

Certara Subsidiaries (8)

Company Name Industry Location Founded
Vyasa Analytics Media and Information Services (B2B) Newburyport, MA 2016
Applied BioMath Drug Discovery Concord, MA 0000
Pinnacle 21 Business/Productivity Software Blue Bell, PA 0000
Integrated Nonclinical Development Solutions Other Healthcare Technology Systems Ann Arbor, MI 0000
Formedix Other Healthcare Technology Systems Glasgow, United Kingdom 0000
You’re viewing 5 of 8 subsidiaries. Get the full list »

Certara ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

16.56 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,216

Rank

00.00

Percentile

Healthcare

Industry

00 of 643

Rank

00.00

Percentile

Health Care IT Services

Subindustry

0. of 40

Rank

00.00

Percentile

To view Certara’s complete esg history, request access »

Certara Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
Signase 30-Apr-2002 00000 00000 00 00.00 Completed
  • 2 buyers
Signase 01-May-2000 0000 00000 Completed
  • 3 buyers
Arena Pharmaceuticals 22-Feb-1999 Later Stage VC 0000 Completed
  • 5 buyers
To view Certara’s complete exits history, request access »

Certara FAQs

  • When was Certara founded?

    Certara was founded in 1979.

  • Who is the CEO of Certara?

    William Feehery is the CEO of Certara.

  • Where is Certara headquartered?

    Certara is headquartered in Princeton, NJ.

  • What is the size of Certara?

    Certara has 1,391 total employees.

  • What industry is Certara in?

    Certara’s primary industry is Drug Discovery.

  • Is Certara a private or public company?

    Certara is a Public company.

  • What is Certara’s stock symbol?

    The ticker symbol for Certara is CERT.

  • What is the current stock price of Certara?

    As of 19-Jul-2024 the stock price of Certara is $16.08.

  • What is the current market cap of Certara?

    The current market capitalization of Certara is $2.59B.

  • What is Certara’s current revenue?

    The trailing twelve month revenue for Certara is $361M.

  • Who are Certara’s competitors?

    AbCellera, Cyrus Biotechnology, BioBlocks, SeraCare, and Recursion Pharmaceuticals are some of the 13 competitors of Certara.

  • What is Certara’s annual earnings per share (EPS)?

    Certara’s EPS for 12 months was -$0.39.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »